YouTube · Q2 2026 · 2026-07-23
DHR · NYSE
Danaher Corporation
Diagnostics & Research · United States
- Market cap (USD)
- US$157.74B
- Trailing P/E
- 40.00x
- Forward P/E
- 24.12x
- Quarterly revenue growth
- 5.5%
- Trailing net margin
- 15.9%
- Indicated dividend yield
- 0.7%
Snapshot 2026-10-06 · Latest financial period 2026-06-26 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Next earnings: 2026-10-21 (provider estimate, not issuer-confirmed).
Company background
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Company websiteQ2 2026
Go beyond the headline.
Comparable businesses
DHR peer comparison
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
| Metric | DHRDanaher CorporationSnapshot 2026-10-06Financial period: 2026-06-26 | TMOThermo Fisher Scientific Inc.Snapshot 2026-10-06Financial period: 2026-06-27 | NTRANatera, Inc.Snapshot 2026-10-06Financial period: 2026-06-30 | Peer medianSimilar-size peers only |
|---|---|---|---|---|
| Market capMarket value, converted to USD | US$157.74B | US$251.81B | US$60.59B | US$156.20Bn=2 |
| Forward P/EProvider forward earnings estimate | 24.12x | 24.72x | — | — |
| EV / EBITDAEnterprise value / trailing EBITDA | 22.30x | 24.61x | — | — |
| Revenue growthLatest quarter vs prior-year quarter | 5.5% | 10.5% | 37.7% | 24.1%n=2 |
| Operating marginLatest reported quarter | 19.8% | 18.8% | -10.3% | 4.2%n=2 |
| Free cash flow yieldTrailing cash flow / market cap | 2.7% | 2.5% | 0.2% | 1.3%n=2 |
| Net debt / EBITDANet debt / trailing EBITDA | 2.93x | 3.28x | — | — |
| Debt / equityTotal debt / positive book equity | 0.53x | 0.81x | 0.13x | 0.47xn=2 |
| Trailing P/ETrailing twelve-month earnings | 40.00x | 36.65x | — | — |
| Price / bookPrice / positive book equity per share | 3.00x | 4.78x | 33.14x | 18.96xn=2 |
| EV / salesEnterprise value / trailing revenue | 7.13x | 6.23x | 22.35x | 14.29xn=2 |
| Earnings growthLatest quarter vs prior-year quarter | 59.7% | 9.4% | — | — |
| Gross marginTrailing twelve months | 58.8% | 41.0% | 65.2% | 53.1%n=2 |
| Net marginTrailing twelve months | 15.9% | 15.0% | -7.1% | 4.0%n=2 |
| Return on equityProvider trailing return; positive equity only | 7.6% | 13.5% | -12.5% | 0.5%n=2 |
| Free cash flow marginTrailing free cash flow / revenue | 17.2% | 13.5% | 3.8% | 8.7%n=2 |
| Dividend yieldIndicated annual dividend / price | 0.7% | 0.3% | — | — |
| Earnings payoutProvider trailing dividend payout | 25.7% | 9.7% | — | — |
| Current ratioCurrent assets / current liabilities | 1.65x | 1.55x | 3.00x | 2.27xn=2 |
| BetaProvider historical market sensitivity | 0.80 | 0.88 | 1.50 | 1.19n=2 |
YouTube · Q2 2026 · 2026-07-23
YouTube · Q2 2026 · 2026-08-07
Comparison methodology & limitations
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Financial trends
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Revenue
Reported figures
Financial data & calculation notes
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Valuation & price history
Adjusted closing price
Price history loads separately.
Price figures
Earnings-multiple scenario
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-10-06. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
Research history for DHR
Q2 20262026-07-21
Danaher Stock: It Beat Earnings and RAISED Guidance — So Why Did DHR Fall? (Our Call: HOLD)
Presentation · 2026-07-21 · YouTube
Q1 20262026-04-21
DHR Stock: EPS Beats by 6% — Q1 2026 Earnings Analysis
Presentation · 2026-04-21 · YouTube
Deep Dive2026-04-21
Q4 20252026-04-15
DHR Stock: $6.8B Revenue — Q4 2025 Earnings Analysis
Presentation · 2026-04-15 · YouTube
DHR Stock: $6.8B Revenue — Q4 2025 Earnings Analysis
Presentation · 2026-04-15 · YouTube